Pancreatic Cancer Research

ResearcherIkeda Municipal HospitalActive in the last 2 years

Osakuni Morimoto

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5028059431. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 8

  1. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenoca… Co-author DOI 10.1038/s41598-025-23185-7↗
  2. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  3. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  4. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
  5. [A Case of Pancreatic Pseudocyst Recurrence after Surgery for Remnant Pancreatic Cancer]. Co-author PMID 35046330↗
  6. [A Case Report of Long Survival in Pancreatic Cancer with Superior Mesenteric Arterial Invasion Following Multimodal Therapy]. Co-author PMID 32156925↗
  7. [A Case of Chemotherapy with Abscess Drainage for Pancreatic Cancer Detected Due to Peritonitis]. First author PMID 32156964↗
  8. [Multidisciplinary therapy for recurrent pancreatic cancer]. Co-author PMID 25731460↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masahiro Tanemura · 4 shared papers, 2021–2025 · strength 0.65
  2. Tadafumi Asaoka · 4 shared papers, 2021–2025 · strength 0.65
  3. Yuichiro Doki · 4 shared papers, 2021–2025 · strength 0.65
  4. Masanori Tsujie · 4 shared papers, 2021–2025 · strength 0.65
  5. Hirofumi Akita · 4 shared papers, 2021–2025 · strength 0.65
  6. Daisaku Yamada · 4 shared papers, 2021–2025 · strength 0.65
  7. Yutaka Takeda · 4 shared papers, 2021–2025 · strength 0.65
  8. Yoshifumi Iwagami · 3 shared papers, 2024–2025 · strength 0.55
  9. Hidetoshi Eguchi · 3 shared papers, 2021–2024 · strength 0.45
  10. Hidenori Takahashi · 3 shared papers, 2021–2024 · strength 0.45
  11. Yusuke Akamaru · 3 shared papers, 2019–2021 · strength 0.27
  12. Hirotsugu Ohashi · 3 shared papers, 2019–2021 · strength 0.27
  13. Daisuke Takiuchi · 3 shared papers, 2014–2021 · strength 0.23
  14. Hidetoshi Eguchi · 1 shared paper, 2025 · strength 0.20
  15. Kunitaka Shibata · 2 shared papers, 2014–2019 · strength 0.12
  16. Takahiro Shimaoka · 1 shared paper, 2021 · strength 0.11
  17. Kunitaka Shibata · 1 shared paper, 2021 · strength 0.11
  18. Masahiro Murakami · 1 shared paper, 2021 · strength 0.10
  19. 瀧内 大輔 · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.